用于CD30淋巴瘤的具有延长半衰期的四价NK细胞结合双特异性抗体的设计与功能表征 - Suppr

Suppr

超能文献

Design and functional characterization of a tetravalent NK cell-engaging bispecific antibody with enhanced half-life for CD30 lymphoma.

作者信息

Zhao Caizhi, Xie Liping, Wang Ming-Wei, Hu Youjia

机构信息

School of Pharmacy, Fudan University, Shanghai 201203, China.

China State Institute of Pharmaceutical Industry, Shanghai 201203, China.

出版信息

Acta Pharm Sin B. 2025 May;15(5):2778-2782. doi: 10.1016/j.apsb.2025.03.012. Epub 2025 Mar 8.

DOI:10.1016/j.apsb.2025.03.012

PMID:40487655

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12145002/

Abstract

摘要

相似文献

Design and functional characterization of a tetravalent NK cell-engaging bispecific antibody with enhanced half-life for CD30 lymphoma.用于CD30淋巴瘤的具有延长半衰期的四价NK细胞结合双特异性抗体的设计与功能表征

Acta Pharm Sin B. 2025 May;15(5):2778-2782. doi: 10.1016/j.apsb.2025.03.012. Epub 2025 Mar 8.

Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30 Malignancies.将 AFM13（一种双特异性 CD30/CD16 抗体）与细胞因子激活的血液和脐带血来源的 NK 细胞联合使用，可促进针对 CD30 恶性肿瘤的类似 CAR 的反应。

Clin Cancer Res. 2021 Jul 1;27(13):3744-3756. doi: 10.1158/1078-0432.CCR-21-0164. Epub 2021 May 13.

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.一种新型四价双特异性串联抗体（CD30/CD16A）可有效募集自然杀伤细胞以裂解CD30+肿瘤细胞。

MAbs. 2014 May-Jun;6(3):728-39. doi: 10.4161/mabs.28591. Epub 2014 Mar 26.

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.AFM13：一种用于自然杀伤细胞介导的免疫疗法的一流四价双特异性抗CD30/CD16A抗体。

J Hematol Oncol. 2015 Aug 1;8:96. doi: 10.1186/s13045-015-0188-3.

Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.将单链抗体片段（scFv）插入全长IgG1单克隆抗体的铰链区可产生具有强大特性的四价双特异性分子。

MAbs. 2017 Feb/Mar;9(2):240-256. doi: 10.1080/19420862.2016.1270492.

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.一种四价双特异性串联抗体（CD19/CD3）AFM11能够有效募集T细胞，从而有力地裂解CD19(+)肿瘤细胞。

MAbs. 2015;7(3):584-604. doi: 10.1080/19420862.2015.1029216.

Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.抗CD30单链抗体片段-免疫球蛋白Fc段-白细胞介素-2抗体-细胞因子融合蛋白，可诱导静息自然杀伤细胞对霍奇金淋巴瘤来源的肿瘤细胞进行高效细胞溶解。

Int J Cancer. 2004 Jun 20;110(3):386-94. doi: 10.1002/ijc.20098.

Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.替布珠单抗的研发，一种针对 BAFF 和 IL-17A 的四价双特异性抗体，用于治疗自身免疫性疾病。

MAbs. 2019 Aug/Sep;11(6):1175-1190. doi: 10.1080/19420862.2019.1624463. Epub 2019 Jun 10.

Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens.一种新型四价双特异性抗体的产生及其与乙型肝炎病毒表面抗原结合特性的研究

Mol Immunol. 2000 Dec;37(18):1123-30. doi: 10.1016/s0161-5890(01)00027-x.

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.抗CD16/抗CD30双特异性抗体在体内系统中的靶向特性

Cancer Immunol Immunother. 2001 Apr;50(2):102-8. doi: 10.1007/s002620100172.

本文引用的文献

AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.AFM13 治疗复发或难治性经典霍奇金淋巴瘤患者：一项开放标签、随机、多中心 II 期试验的最终结果。

Leuk Lymphoma. 2022 Aug;63(8):1871-1878. doi: 10.1080/10428194.2022.2095623. Epub 2022 Jul 18.

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma.一种用于治疗多发性骨髓瘤的 BCMA/CD16A 双特异性先天细胞接合器。

Leukemia. 2022 Apr;36(4):1006-1014. doi: 10.1038/s41375-021-01478-w. Epub 2022 Jan 10.

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.新型 CD16A 特异性固有免疫细胞衔接子 AFM24 对表皮生长因子受体阳性肿瘤的临床前评估。

MAbs. 2021 Jan-Dec;13(1):1950264. doi: 10.1080/19420862.2021.1950264.

Exploring the NK cell platform for cancer immunotherapy.探索自然杀伤细胞平台在癌症免疫疗法中的应用。

Nat Rev Clin Oncol. 2021 Feb;18(2):85-100. doi: 10.1038/s41571-020-0426-7. Epub 2020 Sep 15.

A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation.一种新型未成熟自然杀伤细胞亚群可预测脐血移植后复发。

Blood Adv. 2019 Dec 10;3(23):4117-4130. doi: 10.1182/bloodadvances.2019000835.

CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.NK 细胞的 CD16A 激活促进 NK 细胞增殖和对癌细胞的记忆样细胞毒性。

Cancer Immunol Res. 2018 May;6(5):517-527. doi: 10.1158/2326-6066.CIR-17-0550. Epub 2018 Mar 7.

IgG subclasses and allotypes: from structure to effector functions.IgG亚类与同种异型：从结构到效应功能

Front Immunol. 2014 Oct 20;5:520. doi: 10.3389/fimmu.2014.00520. eCollection 2014.

MAbs. 2014 May-Jun;6(3):728-39. doi: 10.4161/mabs.28591. Epub 2014 Mar 26.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.一项评估 Brentuximab vedotin 治疗复发或难治性霍奇金淋巴瘤患者的关键性 II 期研究结果。

J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.

Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.低岩藻糖基化IgG1抗体增强自然杀伤细胞的结合与激活，可在较低抗原密度下有效诱导抗体依赖性细胞毒性。

Clin Cancer Res. 2005 Mar 15;11(6):2327-36. doi: 10.1158/1078-0432.CCR-04-2263.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验